Valuation: argenx SE

Market Cap 53.75B 46.73B 43.49B 39.93B 75.41B 5,131B 76.58B 513B 201B 2,555B 202B 197B 8,566B P/E 2026 *
31.7x
P/E 2027 * 25.4x
Enterprise Value 48.39B 42.07B 39.16B 35.95B 67.89B 4,620B 68.94B 462B 181B 2,300B 182B 178B 7,712B EV / Sales 2026 *
7.83x
EV / Sales 2027 * 6.06x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day-0.21%
1 week-7.38%
Current month-8.18%
1 month-6.12%
3 months+8.85%
6 months+4.40%
Current year+3.93%
1 week 738
Extreme 738
811.3
1 month 735
Extreme 735
833.6
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.28
Extreme 12.28
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-7.38%+25.34%+63.02% 53.75B
+2.35%+0.77%+29.92%+85.38% 55.23B
-2.28%+1.97%-15.27%-16.33% 23.48B
-3.54%-8.32%-8.63%+343.73% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-1.06%+29.29%-33.32% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-4.95%-3.43%+47.63%+171.28% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
-6.53%-15.08%+52.86%+125.24% 11.37B
Average -0.78%-1.44%+36.34%+153.25% 24.48B
Weighted average by Cap. -0.16%+0.02%+28.71%+121.09%

Financials

2026 *2027 *
Net sales 6.18B 5.37B 5B 4.59B 8.67B 590B 8.81B 58.95B 23.14B 294B 23.21B 22.7B 985B 7.59B 6.6B 6.14B 5.64B 10.65B 725B 10.82B 72.43B 28.43B 361B 28.52B 27.89B 1,210B
Net income 1.84B 1.6B 1.49B 1.36B 2.58B 175B 2.62B 17.52B 6.88B 87.29B 6.9B 6.75B 293B 2.44B 2.12B 1.97B 1.81B 3.42B 233B 3.48B 23.28B 9.14B 116B 9.17B 8.97B 389B
Net Debt -5.36B -4.66B -4.34B -3.98B -7.52B -512B -7.64B -51.13B -20.07B -255B -20.13B -19.69B -854B -7.74B -6.73B -6.26B -5.75B -10.86B -739B -11.03B -73.82B -28.97B -368B -29.07B -28.43B -1,233B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-07-31 745.00 -0.21% 96,817
26-07-30 €746.60 -3.74% 97,191
26-07-29 €775.60 +0.47% 72,563
26-07-28 €772.00 -2.25% 84,929
26-07-27 €789.80 -1.82% 101,165
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
859.54USD
Average target price
1,032.21USD
Spread / Average Target
+20.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock